Daniel A. Norris

4.3k citations

39 papers · 3.5k · 4 hit papers · h-index 23

Impact in

Genetics top 1%
- Neurogenetic and Muscular Disorders Research
Pharmaceutical Science top 1%
- Advanced Drug Delivery Systems

Papers in

Genetics 12
- Neurogenetic and Muscular Disorders Research 12
Hepatology 9
- Hepatitis C virus research 9

Co-authors: C. Frank Bennett (12 shared papers)Richard S. Geary (3 shared papers)Rosie Z. Yu (3 shared papers)Patrick J. Sinko (3 shared papers)Kathie M. Bishop (8 shared papers)Claudia A. Chiriboga (7 shared papers)Jacqueline Montes (7 shared papers)Darryl C. De Vivo (7 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (9 papers)Neurology (8 papers)Neuromuscular Disorders (3 papers)Advanced Drug Delivery Reviews (2 papers)CPT Pharmacometrics & Systems Pharmacology (2 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Daniel A. Norris

39 papers receiving 3.4k citations

Daniel A. Norris's Hit Papers

align trajectories log scale

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial 2023 · 217 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2023 Nature Medicine
2019 UCL Discovery (University College London)
2016 Neurology
2015 Advanced Drug Delivery Reviews

Peers

Countries citing papers authored by Daniel A. Norris

Since Specialization

Citations

This map shows the geographic impact of Daniel A. Norris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Norris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Norris more than expected).

Fields of papers citing papers by Daniel A. Norris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Norris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Norris. The network helps show where Daniel A. Norris may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel A. Norris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel A. Norris Line = papers co-authored together Daniel A. Norris links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides Advanced Drug Delivery Reviews ·Richard S. Geary, Daniel A. Norris, Rosie Z. Yu, C. Frank Bennett Hit paper breakdown →	2015	730
2	Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy Neurology ·Claudia A. Chiriboga, Kathryn J. Swoboda, Basil T. Darras, Susan T. Iannaccone, Jacqueline Montes, Darryl C. De Vivo, Daniel A. Norris, C. Frank Bennett Hit paper breakdown →	2016	527
3	Targeting Huntingtin Expression in Patients with Huntington's Disease UCL Discovery (University College London) ·Sarah J Tabrizi, Blair R. Leavitt, Anne Elizabeth Rosser, Holly B. Kordasiewicz, Christian Czech, Eric E. Swayze, Daniel A. Norris, Tiffany L. Baumann Hit paper breakdown →	2019	407
4	Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates Journal of Pharmacology and Experimental Therapeutics ·Frank Rigo, Seung Joo Chun, Daniel A. Norris, Gene Hung, Sam S. Lee, John E. Matson, Robert A. Fey, Hans J. Gaus	2014	242
5	The effect of physical barriers and properties on the oral absorption of particulates Advanced Drug Delivery Reviews ·Daniel A. Norris	1998	217
6	Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial Nature Medicine ·Catherine Jane Mummery, Anne Börjesson‐Hanson, Daniel J. Blackburn, Everard G.B. Vijverberg, Peter Paul De Deyn, Simon Ducharme, Michael A. G. Jonsson, Anja Schneider Hit paper breakdown →	2023	217
7	Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells Pharmaceutical Research ·Vijaya D. Makhey, Ailan Guo, Daniel A. Norris, Peidi Hu, Jiansheng Yan, Patrick J. Sinko	1998	195
8	Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin Journal of Applied Polymer Science ·Daniel A. Norris, Patrick J. Sinko	1997	161
9	Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment Journal of Clinical Investigation ·Daniel Marin Ramos, Constantin van Outryve d’Ydewalle, Vijayalakshmi Gabbeta, Amal Dakka, Stephanie Kristin Klein, Daniel A. Norris, John E. Matson, Shannon J. Taylor	2019	157
10	Development of predictive pharmacokinetic simulation models for drug discovery Journal of Controlled Release ·Daniel A. Norris, Glen D. Leesman, Patrick J. Sinko, George M. Grass	2000	94
11	Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys Nucleic Acid Therapeutics ·Sebastien A. Burel, So-Ri Han, Hong-Soo Lee, Daniel A. Norris, Byoung‐Seok Lee, Todd Machemer, Shin‐Young Park, Tianyuan Zhou	2013	69
12	A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration Journal of Pharmacokinetics and Pharmacodynamics ·Michael I. Monine, Daniel A. Norris, Yanfeng Wang, Ivan A. Nestorov	2021	51
13	Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations The Journal of Clinical Pharmacology ·Kenneth T. Luu, Daniel A. Norris, Rudy Gunawan, Scott P. Henry, Richard S. Geary, Yanfeng Wang	2017	47
14	Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Frank Ruebsam, Douglas E. Murphy, Chinh V. Tran, Lian‐Sheng Li, Jingjing Zhao, Peter S. Dragovich, Helen Marie McGuire, Alan X. Xiang	2009	42
15	Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Frank Ruebsam, Stephen E. Webber, Martin T. Tran, Chinh V. Tran, Douglas E. Murphy, Jingjing Zhao, Peter S. Dragovich, Sun Hee Kim	2008	36
16	Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments Bioorganic & Medicinal Chemistry Letters ·Lian‐Sheng Li, Yuefen Zhou, Douglas E. Murphy, Nebojsa S. Stankovic, Jingjing Zhao, Peter S. Dragovich, Thomas M. Bertolini, Zhongxiang Sun	2008	31
17	Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOs Molecular Therapy — Nucleic Acids ·Colby S. Shemesh, Rosie Z. Yu, Mark S. Warren, Michael Liu, Mirza Jahic, Brandon Nichols, Noah M. Post, Song Lin	2017	30
18	Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Sun Hee Kim, Martin T. Tran, Frank Ruebsam, Alan X. Xiang, Benjamin K. Ayida, Helen Marie McGuire, David Ellis, Julie K. Blazel	2008	28
19	Design of the First-in-Human Study of IONIS-MAPTRx, a Tau-lowering Antisense Oligonucleotide, in Patients With Alzheimer Disease (S2.006) Neurology ·Laurence Mignon, Holly B. Kordasiewicz, Roger M. Lane, Anne V. Smith, Timothy M. Miller, Padma Kumar Narayanan, Eric E. Swayze, Daniel A. Norris	2018	26
20	5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase Bioorganic & Medicinal Chemistry Letters ·Frank Ruebsam, Chinh V. Tran, Lian‐Sheng Li, Sun Hee Kim, Alan X. Xiang, Yuefen Zhou, Julie K. Blazel, Zhongxiang Sun	2008	25

About Daniel A. Norris

Daniel A. Norris is a scholar working on Genetics, Hepatology, Infectious Diseases, Pharmaceutical Science and Molecular Biology, having authored 39 papers that have together received 3.5k indexed citations. Recurring topics across this work include Neurogenetic and Muscular Disorders Research (12 papers), HIV/AIDS drug development and treatment (9 papers), Hepatitis C virus research (9 papers), RNA modifications and cancer (5 papers), Quinazolinone synthesis and applications (5 papers), RNA Interference and Gene Delivery (4 papers), Genetic Neurodegenerative Diseases (4 papers) and DNA and Nucleic Acid Chemistry (4 papers). The work is most often cited by research in Genetics (809 citations), Pharmaceutical Science (343 citations), Molecular Biology (2.0k citations), Cellular and Molecular Neuroscience (490 citations) and Hepatology (152 citations). Daniel A. Norris has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include C. Frank Bennett, Richard S. Geary, Rosie Z. Yu, Patrick J. Sinko, Kathie M. Bishop, Claudia A. Chiriboga, Jacqueline Montes, Darryl C. De Vivo, Basil T. Darras and Kathryn J. Swoboda. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Neurology, Neuromuscular Disorders, Advanced Drug Delivery Reviews and CPT Pharmacometrics & Systems Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Daniel A. Norris

Impact in

Papers in i

In The Last Decade

Daniel A. Norris

Daniel A. Norris's Hit Papers

Peers

Countries citing papers authored by Daniel A. Norris

Fields of papers citing papers by Daniel A. Norris

All Works

About Daniel A. Norris

Explore authors with similar magnitude of impact

Papers in